Recent Advances in Cancer Imaging with ⁶⁴CuCl₂ PET/CT.

IF 1.3 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Nuclear Medicine and Molecular Imaging Pub Date : 2022-04-01 DOI:10.1007/s13139-022-00738-6

Fangyu Peng

{"title":"Recent Advances in Cancer Imaging with 64CuCl2 PET/CT.","authors":"Fangyu Peng","doi":"10.1007/s13139-022-00738-6","DOIUrl":null,"url":null,"abstract":"Copper is required for cancer cell proliferation and tumor angiogenesis. Radioactive copper-64 chloride (64CuCl2) is a useful radiotracer for cancer imaging with position emission tomography (PET) based on increased cellular uptake of copper mediated by human copper transporter 1 (hCtr1) expressed on cancer cell membrane. Significant progress has been made in research of using 64CuCl2 as a radiotracer for cancer imaging with PET. Radiation dosimetry study in humans demonstrated radiation safety of 64CuCl2. Recently, 64CuCl2 was successfully used for PET imaging of prostate cancer, bladder cancer, glioblastoma multiforme (GBM), and non-small cell lung carcinoma in humans. Based on the findings from the preclinical research studies, 64CuCl2 PET/CT also holds potential for diagnostic imaging of human hepatocellular carcinoma (HCC), malignant melanoma, and detection of intracranial metastasis of copper-avid tumors based on low physiological background of radioactive copper uptake in the brain. Copper-64 radionuclide emits both β+ and β- particles, suggesting therapeutic potential of 64CuCl2 for radionuclide cancer therapy of copper-avid tumors. Recent progress in production of therapeutic copper-67 radionuclide invites clinical research in use of theranostic pair of 64CuCl2 and 67CuCl2 for cancer imaging and radionuclide therapy.","PeriodicalId":19384,"journal":{"name":"Nuclear Medicine and Molecular Imaging","volume":"56 2","pages":"80-85"},"PeriodicalIF":1.3000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976861/pdf/13139_2022_Article_738.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuclear Medicine and Molecular Imaging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13139-022-00738-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 3

Abstract

Copper is required for cancer cell proliferation and tumor angiogenesis. Radioactive copper-64 chloride (⁶⁴CuCl₂) is a useful radiotracer for cancer imaging with position emission tomography (PET) based on increased cellular uptake of copper mediated by human copper transporter 1 (hCtr1) expressed on cancer cell membrane. Significant progress has been made in research of using ⁶⁴CuCl₂ as a radiotracer for cancer imaging with PET. Radiation dosimetry study in humans demonstrated radiation safety of ⁶⁴CuCl₂. Recently, ⁶⁴CuCl₂ was successfully used for PET imaging of prostate cancer, bladder cancer, glioblastoma multiforme (GBM), and non-small cell lung carcinoma in humans. Based on the findings from the preclinical research studies, ⁶⁴CuCl₂ PET/CT also holds potential for diagnostic imaging of human hepatocellular carcinoma (HCC), malignant melanoma, and detection of intracranial metastasis of copper-avid tumors based on low physiological background of radioactive copper uptake in the brain. Copper-64 radionuclide emits both β⁺ and β^- particles, suggesting therapeutic potential of ⁶⁴CuCl₂ for radionuclide cancer therapy of copper-avid tumors. Recent progress in production of therapeutic copper-67 radionuclide invites clinical research in use of theranostic pair of ⁶⁴CuCl₂ and ⁶⁷CuCl₂ for cancer imaging and radionuclide therapy.

Abstract Image

查看原文本刊更多论文

64CuCl2 PET/CT在肿瘤成像中的最新进展。

铜是癌细胞增殖和肿瘤血管生成所必需的。放射性铜64氯化(64CuCl2)是一种有用的癌症位置发射断层扫描(PET)成像的放射性示踪剂，基于癌细胞膜上表达的人类铜转运蛋白1 (hCtr1)介导的细胞对铜的摄取增加。利用64CuCl2作为放射性示踪剂用于PET癌症成像的研究取得了重大进展。人体辐射剂量学研究表明64CuCl2具有辐射安全性。最近，64CuCl2被成功地用于人类前列腺癌、膀胱癌、多形性胶质母细胞瘤(GBM)和非小细胞肺癌的PET成像。基于临床前研究结果，64CuCl2 PET/CT在人类肝细胞癌(HCC)、恶性黑色素瘤的诊断成像以及基于低脑放射性铜摄取生理背景的嗜铜肿瘤颅内转移检测方面也具有潜力。铜-64核素同时释放β+和β-粒子，提示64CuCl2在缺铜肿瘤的放射性核素癌治疗中具有潜在的治疗潜力。治疗性铜-67核素生产的最新进展促使临床研究利用64CuCl2和67CuCl2治疗性对进行癌症成像和放射性核素治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nuclear Medicine and Molecular Imaging RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-

CiteScore

2.20

自引率

7.70%

发文量

期刊介绍： Nuclear Medicine and Molecular Imaging (Nucl Med Mol Imaging) is an official journal of the Korean Society of Nuclear Medicine, which bimonthly publishes papers on February, April, June, August, October, and December about nuclear medicine and related sciences such as radiochemistry, radiopharmacy, dosimetry and pharmacokinetics / pharmacodynamics of radiopharmaceuticals, nuclear and molecular imaging analysis, nuclear and molecular imaging instrumentation, radiation biology and radionuclide therapy. The journal specially welcomes works of artificial intelligence applied to nuclear medicine. The journal will also welcome original works relating to molecular imaging research such as the development of molecular imaging probes, reporter imaging assays, imaging cell trafficking, imaging endo(exo)genous gene expression, and imaging signal transduction. Nucl Med Mol Imaging publishes the following types of papers: original articles, reviews, case reports, editorials, interesting images, and letters to the editor. The Korean Society of Nuclear Medicine (KSNM) KSNM is a scientific and professional organization founded in 1961 and a member of the Korean Academy of Medical Sciences of the Korean Medical Association which was established by The Medical Services Law. The aims of KSNM are the promotion of nuclear medicine and cooperation of each member. The business of KSNM includes holding academic meetings and symposia, the publication of journals and books, planning and research of promoting science and health, and training and qualification of nuclear medicine specialists.